Topotecan-d5

Topotecan-d5 is the deuterium labeled Topotecan. Topotecan (SKF 104864A; NSC 609669) is a Topoisomerase I inhibitor. The IC50 values of Topotecan at 24 h are 2.73±0.25 μM of U251 cells, 2.95±0.23 μM of U87 cells, 5.46±0.41 μM of GSCs-U251 and 5.95±0.24 μM of GSCs-U87[1][2].

Product Specifications

CAS Number

[1133355-98-2]

Product Name Alternative

SKF 104864A-d5; NSC 609669-d5

UNSPSC

12352005

Target

Autophagy; Isotope-Labeled Compounds; Topoisomerase

Related Pathways

Autophagy; Cell Cycle/DNA Damage; Others

Field of Research

Cancer

Solubility

10 mM in DMSO

Smiles

[2H]C([2H])([2H])C([2H])([2H])[C@@]1(C2=C(COC1=O)C(N3C(C(C(C3)=CC4=C5CN(C)C)=NC4=CC=C5O)=C2)=O)O

Molecular Formula

C23H18D5N3O5

Molecular Weight

426.48

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Zhang FL, et al. PLoS One. 2013 Nov 26;8 (11) :e81815.Topoisomerase I inhibitors, Shikonin and Topotecan, inhibit growth and induce apoptosis of glioma cells andglioma stem cells.|[3]Kumar S, et al. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. Clin Cancer Res. 2011 Sep 1;17 (17) :5656-67.